| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
We performed this study to clarify molecular mechanisms of abnormal cell proliferation in transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia of Down syndrome (DS-AMKL), and found the following results.
1. We identified 3 novel JAK3 mutations in a DS-AMKL cell line and a TMD patient, and demonstrated that these mutations were all activating mutations.
2. We showed that JAK3 inhibitors would have therapeutic effects on TMD and DS-AMKL patients carrying activating JAK3 mutations.
|
